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Abstract
External pilot trials of complex interventions are used to help deter-
mine if and how a confirmatory trial should be undertaken, providing es-
timates of parameters such as recruitment, retention and adherence rates.
The decision to progress to the confirmatory trial is typically made by
comparing these estimates to pre-specified thresholds known as progres-
sion criteria, although the statistical properties of such decision rules are
rarely assessed. Such assessment is complicated by several methodological
challenges, including the simultaneous evaluation of multiple endpoints,
complex multi-level models, small sample sizes, and uncertainty in nui-
sance parameters. In response to these challenges, we describe a Bayesian
approach to the design and analysis of external pilot trials. We show how
progression decisions can be made by minimising the expected value of a
loss function, defined over the whole parameter space to allow for pref-
erences and trade-offs between multiple parameters to be articulated and
used in the decision making process. The assessment of preferences is kept
feasible by using a piecewise constant parametrisation of the loss function,
the parameters of which are chosen at the design stage to lead to desir-
able operating characteristics. We describe a flexible, yet computationally
intensive, nested Monte Carlo algorithm for estimating operating charac-
teristics. The method is used to revisit the design of an external pilot
trial of a complex intervention designed to increase the physical activity
of care home residents.
1 Introduction
Complex interventions, defined as those comprised of several interacting compo-
nents [1], can be challenging to evaluate in randomised controlled trials (RCTs)
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due to factors such as slow patient recruitment, poor levels of adherence to the
intervention, and low completeness of follow-up data. To identify these prob-
lems prior to the main RCT we often conduct small trials [1] known as pilots.
These typically take the same form as the planned RCT but with a considerably
lower sample size [2]. If there is a seamless transition between the pilot and the
main RCT, with all data being pooled and used in the final analysis, they are
known as internal pilots. External pilots, in contrast, are carried out separately
to the main RCT with a clear gap between the two trials. Pilot trials, which
aim to inform the feasibility and optimal design of a subsequent definitive trial
[3], are distinct from phase II trials, which focus instead on assessing potential
efficacy and safety.
The data generated by an external pilot trial is used to help decide if the
main RCT should go ahead, and if so, whether the intervention or the trial
design should be adjusted to ensure success. In the UK, the National Insti-
tute for Health Research ask that these progression criteria are pre-specified
and included in the research plan [4], and the recent CONSORT extension to
randomised pilot trials requires their reporting [5]. A single pilot trial can col-
lect data on several progression criteria, often focused on the aforementioned
areas of recruitment, protocol adherence, and data collection [6]. Although they
may take the form of single threshold values leading to binary stop/go decision
rules, investigators are increasingly using two thresholds to accommodate an
intermediate decision between stopping altogether and progressing straight to
the main trial, which would allow progression but only after some adjustments
have been made [5]. The need for appropriate progression criteria is clear when
we consider the consequences of poor post-pilot progression decisions. If the
criteria are too lax, there is a greater risk that the main trial will go ahead but
found to be infeasible and thus a waste of resources; if the criteria are too strict,
a promising intervention may be discarded under the mistaken belief that the
main trial would be infeasible. Despite this, there is little published guidance
about how they should be determined[6, 7].
In addition to pre-specifying progression criteria, another key design deci-
sion is the choice of pilot sample size. Conventional methods of sample size
determination, which focus on ensuring the trial will have sufficient power to
detect a target difference in the primary outcome, are rarely used since they
would lead to a pilot sample size comparable with the main trial sample size.
Several methods for pilot sample size determination instead aim to provide a
sufficiently precise estimate of the variance in the primary outcome measure
to inform the sample size of the main trial [8, 9, 10, 11, 12, 13]. Others have
suggested a simple rule of thumb for when the goal is to identify unforeseen
problems [14]. While some have noted that the low sample size in pilots may
lead to a considerable probability that a certain progression criterion will be
met (or missed) due to random sampling variation [12, 15], and despite the con-
sequences of making the wrong progression decision, the statistical properties
of pilot decision rules are rarely used to inform the choice of sample size. This
may be due to the methodological challenges commonly found in pilot trials of
complex interventions, including the simultaneous evaluation of multiple end-
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points, complex multi-level models, small sample sizes, and prior uncertainty in
nuisance parameters [16].
In this paper we will describe a method for designing and analysing external
pilot trials which addresses these challenges. We take a Bayesian view, where
progression decisions are made to minimise the expected value of a loss func-
tion. We propose a loss function with three parameters whose values can be
determined either through direct elicitation of preferences or by considering the
pilot trial operating characteristics they lead to. The operating characteristics
we propose are all unconditional probabilities (with respect to a prior distri-
bution) of making incorrect decisions, also known as assurances [17]. Using
assurances rather than the analogous frequentist error rates brings several ben-
efits, including the ability to make use of existing knowledge whilst allowing for
any uncertainty, and a more natural interpretation [18]. As we will show, as-
surances are also useful when our preferences for different end-of-trial decisions
are based on several attributes in a complex way that involves trading off some
against others.
The remainder of this paper is organised as follows. In Section 2 we describe
the general framework for pilot design and analysis, some operating characteris-
tics used for evaluation, and a routine for optimising the design. Two illustrative
examples are then described in Sections 3 and 4. Finally, we discuss implications
and limitations in Section 5.
2 Methods
2.1 Prior specification
Consider a pilot trial which will produce data x according to model p(x|θ). We
decompose the parameters into θ = (φ, ψ), where φ denotes the parameters of
substantive interest and ψ the nuisance parameters. We follow [19] and assume
that two joint prior distributions of θ have been specified. First, the analysis
prior pA(θ) is that which will be used when fitting the model once the pilot
data is obtained. It has been argued that regulators are unlikely to accept the
prior beliefs of the trial sponsor for analysis of the data [17, 20], and as such a
weakly or non-informative prior should be used for pA(θ) in order to “let the
data drive the inference” [19]. The choice of such a prior will be depend on the
specific model being used, although methodological guidance for various specific
cases such as logistic regression [21] and hierarchical models [22] is available. It
should be emphasised, however, that the typically small sample size of a pilot
trial can mean the effect of the analysis prior is non-negligible. As such, the
analysis prior should provide a credible and justifiable representation of prior
ignorance, avoiding extreme default choices which may place too much prior
weight on infeasible regions of the parameter space.
The design prior pD(θ) will be used when evaluating the statistical perfor-
mance of a proposed pilot trial design. It may be considered as purely hypo-
thetical in the spirit of a ‘what-if’ analysis [19], in which case several candidate
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design priors may be suggested and performance evaluated under each of these.
Alternatively, and as we will assume in the remainder of this paper, pD(θ) can
be a completely subjective prior which fully expresses our knowledge and uncer-
tainty in the parameters at the design stage. Although eliciting such a prior is
potentially challenging, many examples describing successful practical applica-
tions of expert elicitation for clinical trial design are available [20, 18, 23], as are
tools for its conduct such as the Sheffield Elicitation Framework (SHELF) [24].
2.2 Analysis and progression decisions
After observing the pilot data x, we must decide whether or not to progress to
the main RCT. We consider three possible actions following the aforementioned
‘traffic light’ system commonly used in pilot trials:
• red - discard the intervention and stop all future development or evalua-
tion;
• amber - proceed to the main RCT, but only after some modifications to
the intervention, the planned trial design, or both; or
• green - proceed immediately to the main RCT.
In what follows we will denote these decisions by r, a and g respectively. We
assume that our preferences between the three possible decisions are influenced
by φ but independent of ψ, formalising the separation of θ into substantive
and nuisance components. We partition the substantive parameter space Φ into
three subspaces ΦI , for I = R,A,G. Each subspace label corresponds to the
decision we would make if we knew the true value of φ. For example, if φ ∈ ΦR
then the optimal decision is r(ed) - halt development and do not proceed to a
definitive trial. We will henceforth refer to these three subsets as hypotheses.
Throughout, we will distinguish hypothesis I from the corresponding optimal
decision i by using upper and lower case letters respectively.
When φ ∈ ΦI and we choose a decision j 6= i, there will be negative con-
sequences. In particular, we may make three kinds of mistakes: proceed to an
infeasible main RCT; discard a promising intervention; or make unnecessary ad-
justments to the intervention or trial design. We denote these errors as E1, E2,
E3 respectively. The occurrence of error j will be denoted by Ej = 1, otherwise
Ej = 0. An error’s occurrence will be a function of the decision made d and the
true parameter value φ, i.e. Ej(d, φ) : {r, a, g} × Φ → {0, 1} for j = 1, 2, 3. We
then use a loss function to express the preferences of the decision maker(s) on
the space of possible events E1 × E2 × E3 under uncertainty, defined as
L(d, φ) = c1E1(d, φ) + c2E2(d, φ) + c3E3(d, φ).
Note that the additive form of the loss function implies that the our preferences
for any one of the attributes E1, E2, E3 are independent of the values taken by
the others [25].
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Table 1: Losses associated with each decision under each hypothesis.
Hypothesis
φ ∈ ΦR φ ∈ ΦA φ ∈ ΦG
Decision
r 0 c2 c2
a c1 + c3 0 c3
g c1 c1 + c2 0
To determine appropriate values of the parameters c1, c2, c3 we first scale
the loss function by setting c1 + c2 + c3 = 1. Thus, a loss of 0 is obtained if
no errors occur, and a loss of 1 is obtained if all errors occur (although note
that this is not possible in this setting). We then follow the procedure described
by French and Rios Insua (page 99) [25], eliciting some judgements from the
decision maker(s) and using these to determine the values of c1, c2, c3. One
such judgement involves a simple gamble of obtaining the event (E1 = 0, E2 =
0, E3 = 0) with probability 1− p1 and the event (E1 = 1, E2 = 0, E3 = 1) with
probability p1. The decision maker is asked to compare this gamble against an
alternative of obtaining the event (E1 = 1, E2 = 0, E3 = 0) for certain, and to
adjust the value of p1 until they feel indifferent between the two options. Since
this indifference implies the expected losses of the two options are equal, we will
then have
p1(c1 + c3) = c1.
Similarly, we can ask the decision maker(s) to consider a gamble between the
event (E1 = 0, E2 = 0, E3 = 0) with probability 1 − p2 and the event (E1 =
1, E2 = 1, E3 = 0) with probability p2, and compare this against the option of
obtaining (E1 = 1, E2 = 0, E3 = 0) for certain. Again, by determining the value
of p2 which corresponds to indifference and thus equal expected loss, we deduce
that
p2(c1 + c2) = c1.
This gives three equations which can be solved to obtain
c1 =
−p1p2
p1p2 − p1 − p2
, c2 =
p1p2 − p1
p1p2 − p1 − p2
c3 =
p1p2 − p2
p1p2 − p1 − p2
.
Note that the two specific judgements suggested here are only two of many
possible similar questions which could be posed to the decision maker(s). It
is recommended that more indifferences are elicited in order to seek out any
inconsistencies and further clarify their true preferences.
The loss function will then take values as given in Table 1. For example, sup-
pose we make a ‘green’ decision under the ‘amber’ hypothesis. The subsequent
trial will be infeasible because the necessary adjustments will not have been
made; but we have also discarded a promising intervention, since it would have
been redeemed had the adjustments been made. The overall loss is therefore
c1 + c2.
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Given a loss function with parameters c = (c1, c2, c3) we follow the principle
of maximising expected utility (or in our case, minimising the expected loss)
when making a progression decision. We first use the pilot data in conjugation
with the analysis prior pA(θ) to obtain a posterior p(φ | x), and then choose the
decision i∗ such that
i∗ = argmin
i∈{r,a,g}
Eφ|x[L(i, φ)] (1)
= argmin
i∈{r,a,g}
∫
L(i, φ)p(φ|x)dφ. (2)
We can simplify this expression by noting that, given the piecewise constant
nature of the loss function, the expected loss of each decision depends only on
the posterior probabilities pI = Pr[φ ∈ ΦI | x] for I = R,A,G. We then have
Eφ|x[L(r, φ)] = pAc3 + pGc3, (3)
Eφ|x[L(a, φ)] = pRc1 + pRc2 + pGc2, (4)
Eφ|x[L(g, φ)] = pRc1 + pAc1 + pAc3. (5)
For some simple models which admit a conjugate analysis, the posterior prob-
abilities pI can be obtained exactly. Otherwise, Monte Carlo estimates can
be computed based on the samples from the joint posterior distribution gen-
erated by an MCMC analysis of the pilot data. Specifically, given M samples
φ(1), φ(2), . . . , φ(M) ∼ p(φ | x),
pI ≈
1
M
M∑
k=1
I(φ(k) ∈ ΦI), (6)
where I(.) is the indicator function.
2.3 Operating characteristics
Defining a loss function and following the steps of the preceding section effec-
tively prescribes a decision rule mapping the pilot data sample space X to the
decision space {r, a, g}. To gain some insight at the design stage into the prop-
erties of this rule, we propose to calculate some trial operating characteristics.
These take the form of unconditional probabilities of making an error when fol-
lowing the rule, calculated with respect to the design prior pD(θ). We consider
the following:
• OC1 = Pr[a & φ ∈ ΦR]+Pr[g & φ ∈ ΦR∪ΦA] - probability of proceeding
to an infeasible main RCT;
• OC2 = Pr[r & φ ∈ ΦA∪ΦG]+Pr[g & φ ∈ ΦA] - probability of discarding
a promising intervention;
• OC3 = Pr[a & φ ∈ ΦR ∪ΦG] - probability of making unnecessary adjust-
ments to the intervention or the trial design.
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These operating characteristics can be estimated using simulation. First,
we draw N samples (θ(1), x(1)), (θ(2), x(2)), . . . , (θ(N), x(N)) from the joint dis-
tribution p(θ, x) = p(x|θ)pD(θ). For each data set we then apply the analysis
and decision making procedure described in Section 2.2, using some vector c
to parametrise the loss function. This results in N decisions i(k) which can
be contrasted with the corresponding true parameter value θ(k) and in which
hypothesis it resides, noting if any of the three types of errors have been made.
MC estimates of the operating characteristics can then be calculated as the
proportion of occurrences of each type of error in the N simulated cases. As-
suming that N is large, the unbiased MC estimate of an operating characteristic
with true probability p will be approximately normally distributed with variance
p(1− p)/N .1
2.4 Optimisation
Elicitation of the loss function parameters c = (c1, c2, c3) in the manner de-
scribed in Section 2.2 may be challenging, particularly when multiple decision-
makers are involved [26]. An alternative way to determine c is through ex-
amining the operating characteristics it leads to (for some fixed pilot design).
As c is adjusted, the balance between the conflicting objectives of minimising
each OC will change, and the task is then to find the c which returns the best
balance from the perspective of the decision-maker. Formally, and thinking of
operating characteristics as functions of c, we wish to solve the multi-objective
optimisation problem
min
c∈C
(OC1(c), OC2(c), OC3(c)) (7)
where C = {c1, c2 ∈ [0, 1] | c1 + c2 ≤ 1}.
Since the three objectives are in conflict there will be no single solution
which simultaneously minimises each one. We would instead like to find a set
C∗ = {c(1), c(2), . . . , c(K)} such that each member provides a different balance
between minimising the three operating characteristics. If there exist c, c′ ∈ C∗
such that OCi(c
′) ≤ OCi(c) for all i ∈ {1, 2, 3} and OCi(c′) < OCi(c) for
some i ∈ {1, 2, 3}, we say that c′ dominates c. In this case, because c leads to
worse (or at least no better) values of all three operating characteristics when
compared to c′, we have no reason to include it in our set C∗. Because the search
space C has only two dimensions, problem (7) can be approximately solved
by generating a uniform random sample of c’s and estimating the operating
characteristics for each. Any parameters which are dominated in this set can
1Note that in the case of complex models which do no admit a conjugate analysis, the
posterior probabilities obtained using an MCMC analysis will themselves be approximate and
as such the optimal decision will be subject to error, which may increase the variance of the
operating characteristic estimates. However, this issue can be sidestepped by assuming that,
for each data set, the analysis that is simulated corresponds exactly to the analysis that would
be carried out in practice. In particular, we assume that exactly M posterior samples will
be generated by the same MCMC algorithm, using the same seed in the random number
generator.
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then be discarded, and the operating characteristics of those which remain can
be illustrated graphically. The decision maker(s) can then view the range of
available options, all providing different trade-offs amongst the three operating
characteristics, and choose from amongst them.
To solve the problem in a timely manner we must be able to estimate op-
erating characteristics quickly. Noting from equation (3) that the expected loss
of each decision depends only on c and the posterior probabilities pR, pA and
pG, we first generate N samples of these posterior probabilities and then use
this same set of samples for every evaluation. This approach not only ensures
that optimisation is computationally feasible, but also means that differences in
operating characteristics are entirely due to differences in costs, as opposed to
differences in the random posterior probability samples.
3 Illustrative example - Child psychotherapy (TIGA-
CUB)
TIGA-CUB (Trial on Improving Inter-Generational Attachment for Children
Undergoing Behaviour problems) was a two-arm, individually-randomised, con-
trolled pilot trial informing the feasibility and design of a confirmatory RCT
comparing Child Psychotherapy (CP) to Treatment as Usual (TaU), for chil-
dren with treatment resistant conduct disorders. The trial aimed to recruit 60
primary carer-child dyads, to be randomised equally to each arm. This sample
size was chosen to give desired levels of precision in the estimates of the com-
mon standard deviation of the primary outcome, the follow-up rate, and the
adherence rate. Here, we focus on the latter two parameters and consider how
our proposed method could have informed the design of TIGA-CUB.
We model the number of participants successfully followed-up (denoted f)
using a binomial distribution with parameter pf , and similarly the number suc-
cessfully adhering to the intervention (denoted a) with a binomial distribution
with parameter pa. For a fixed pilot trial per-arm sample size n, the parameters
of the model are φ = (pf , pa), with no nuisance parameters. Further assuming
that the numbers followed-up and adhering are independent, the likelihood is
then
p(f, a|pf , pa) =
[(
2n
f
)
pff (1− pf )
2n−f
]
×
[(
n
a
)
paa(1 − pa)
n−a
]
.
At the design stage, the follow-up rate pf was thought to be somewhere in
the range 62% to 92%, while the adherence rate pa was thought to lie between
40% and 95%. We reflect these ranges of uncertainty in our design priors by
using beta distributions pf ∼ Beta(40, 10) (thus giving a prior mean of 0.8), and
pa ∼ Beta(11.2, 4.8) (giving a prior mean of 0.7). We assume that a uniform
‘non-informative’ priorBeta(1, 1) will be used for each parameter in the analysis.
TIGA-CUB’s progression criteria included only simple stop/go thresholds,
with no intermediate ‘amber’ decisions. As such, in this example we partition
8
the parameter space into two hypotheses, ΦG and ΦR. For the purposes of
illustration we define the hypothesis ΦG as the subset of the parameter space
where pf >= 0.8 and pa >= 0.7, hypothesis ΦR being its complement. Thus,
in this example we do not consider there to be a trade-off between the two
parameters of interest. For the main trial to be feasible, both must be above
their respective thresholds. The prior distributions on parameters pf and pa
imply an a priori probability of 0.28 that φ ∈ ΦG, i.e. that both follow-up and
adherence are sufficiently high.
In this special case, the loss function is
L(d, φ) = c1E1(d, φ) + c2E2(d, φ)
and the expected losses of decisions g and r will be Eφ|x[L(g, φ)] = c1pR and
Eφ|x[L(r, φ)] = c2pG, where pR + pG = 1 and c1 + c2 = 1. Decision g is
therefore optimal whenever pG > c1. The posterior probability pG can be
easily calculated given the pilot data due to the beta prior distributions being
conjugate. Specifically, given a total sample size n and observing xf participants
with follow-up and xa participants with adherence, the posterior probability
Pr[φ ∈ ΦG | x] is given by
pG = [1− F (0.8; 1 + xf , 1 + n− xf )]× [1− F (0.7; 1 + xa, 1 + n/2− xa)], (8)
where F (y;α, β) denotes the cumulative probability function of the beta distri-
bution with parameters α, β.
At the design stage we can calculate the probability of an infeasible trial
(OC1),
Pr[g, φ ∈ ΦR] =
∫
ΦR
Pr[g | φ]p(φ)dφ (9)
=
∫
ΦR

 n∑
xf=0

 n/2∑
xa=0
I(pG < c1 | xf , xa, n)p(xa | φ)

 p(xf | φ)

 p(φ)dφ,
(10)
and similarly for the probability of discarding a promising intervention. As these
calculations can be computationally expensive for moderate n due to the nested
summation term, we use Monte Carlo approximations as described in Section 2.
Keeping the sample size fixed at n = 30 per arm, we estimated the operating
characteristics using a range of cost parameters values c1 = 0, 0.02, 0.04, . . . , 1
using M = 106 Monte Carlo samples. The results are plotted in Figure 1, with
some specific values of c1 highlighted. The decision-maker can decide which
point on the operating characteristic curve best reflects their own priorities in
terms of the two types of error. For example, if the consequences of running
an infeasible main RCT are considered less important than those of needlessly
discarding a potentially effective intervention, the decision-maker may choose
to set c1 = 0.2 and would obtain OC1 = 0.19, OC2 = 0.05.
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Figure 1: Probabilities of an infeasible main trial (OC1) and of discarding a
promising intervention (OC2) for a range of loss parameters c1 when sample
size is fixed at n = 30.
To examine the effect of adjusting the sample size, we evaluated the operating
characteristics obtained for n = 10, 12, 14, . . . , 50 per arm whilst setting c1 =
0.2, 0.36, 0.5. The results are shown in Figure 2. Each line includes a shaded
area denoting the 95% Monte Carlo error intervals, although these are so small
as to be illegible given the high number (M = 106) of MC samples used for each
calculation. Although operating characteristics generally improve as the sample
size is increased, we see that for c1 = 0.36 and 0.5 the probability of an infeasible
main trial, OC1, remains flat whilst OC2 has a downward trend. As we would
expect, the the expected loss reduces smoothly as n increases in all cases. In
contrast, there is some variability beyond that explained by MC error in the
OCs. This can be explained by the discrete nature of simulated adherence and
follow-up data. Our results show that, for the design priors and hypotheses used
in this example, the chosen sample size in TIGA-CUB of n = 30 can provide
error rates broadly in line with conventional type I and II error rates under the
usual hypothesis testing framework.
4 Illustrative example - Physical activity in care
homes (REACH)
The REACH (Research Exploring Physical Activity in Care Homes) trial aimed
to inform the feasibility and design of a future definitive RCT assessing a com-
plex intervention designed to increase the physical activity of care home resi-
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Figure 2: Probabilities of an infeasible main trial (OC1) and of discarding a
promising intervention (OC2) for a range of per-arm sample sizes and different
values of the loss parameter c1.
Table 2: Pre-specified progression criteria used in the original REACH design.
Outcome Red Amber Green
Recruitment (avg. per care home) Less than 8 Between 8 and 10 At least 10
Adherence Less than 50% Between 50 and 75% At least 75%
Follow-up Less than 65% Between 65 and 75% At least 75%
dents [27]. The trial was cluster randomised at the care home level, with twelve
care homes in total randomised equally between treatment as usual (TaU) and
the intervention plus TaU.
Data on several feasibility outcomes were collected. Here, we focus on four:
recruitment (measured in terms of the average number of residents in each care
home who participate in the trial, or average cluster size); adherence (a binary
indicator at the care home level indicating if the intervention was fully imple-
mented); data completion (a binary indicator for each resident of successful
follow-up at the planned primary outcome time of 12 months); and potential
efficacy (a continuous measure of physical activity at the resident level). Pro-
gression criteria using the traffic light system were pre-specified for all of these
outcomes except potential efficacy, as detailed in Table 2
Denoting the size of the jth cluster by mj , we assume that cluster sizes
are normally distributed, mj ∼ N(µc, σ
2), j = 1, . . . , 2k. We further assume
that the probability of a participant being followed-up is constant across clus-
ters and arms, and that the total number follows a binomial distribution f ∼
Bin(
∑2k
j=1mj , pf ). The number of care homes which successfully adhere to the
intervention is assumed to binomially distributed, a ∼ Bin(k, pa).
The continuous measure of physical activity is expected to be correlated
within care homes. We model this using a random intercept, where the outcome
yij of resident i in care home j is
yij = Xj × Yj × µ+ uj + εi. (11)
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Here, Xj is a binary indicator of care home j being randomised to the interven-
tion arm, Yj is a binary indicator of care home j successfully adhering to the
intervention, µ is the mean treatment effect, uj ∼ N (0, σ2B) is the random effect
for care home j, and εi ∼ N (0, σ2W ) is the residual for resident i. We parametrise
the model using the intracluster correlation coefficient, ρ = σ2B/(σ
2
B + σ
2
W ).
The parameters describing average cluster size, follow-up and adherence
rates, and mean treatment effect are of substantive interest when making pro-
gression decisions, giving φ = (µc, pf , pa, µ). The remainder are nuisance pa-
rameters, ψ = (σ2, ρ, σ2W ).
4.1 Model specification
To begin specifying a model for the REACH trial, we first note that the four
substantive parameters can be divided into two pairs. Firstly, mean cluster size
and follow-up rate relate to the amount of information which a confirmatory trial
will gather. Secondly, potential efficacy and adherence relate to the effectiveness
of the intervention, where effectiveness is thought of as the effect which will be
obtained in practice when the effect of non-adherence is accounted for. We
expect that a degree of trade-off between adherence and potential efficacy will
be acceptable, with a decrease in one being compensated by an increase in the
other. Likewise, low mean cluster size could be compensated to some extent by
higher follow-up rate, and vice versa.
While there may be trade-offs within these pairs of parameters, we do not
expect trade-offs between them. A trial with no effectiveness will be futile
regardless of the amount of information collected, and so should not be con-
ducted. Similarly, a confirmatory trial should not be conducted if it is highly
unlikely to produce enough information for the research question to be ade-
quately answered. We therefore consider the sub-spaces of Φ formed by these
parameter pairs, partition these into hypotheses, and combine these together.
Constructing hypotheses in these two-dimensional spaces is cognitively simpler
than working in the original four dimensional space, not least because they can
be easily illustrated graphically.
Formally, let Φi be the sub-space of mean cluster size and follow-up rate,
and Φe be that of adherence and potential efficacy. Having specified hypotheses
ΦiI ,Φ
e
I for I = R,A,G, we then have
φ ∈


ΦR if φ
i ∈ ΦiR or φ
e ∈ ΦeR
ΦG if φ
i ∈ ΦiG and φ
e ∈ ΦeG
ΦA otherwise.
(12)
4.1.1 Follow-up and cluster size
Recall that cluster sizes are assumed to be normally distributed with mean µc
and variance σ2). A normal-inverse-gamma prior
σ2 ∼ Γ−1(α0, β0), µc ∼ N(µ0, σ
2/ν0) (13)
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is placed on the mean and variance to allow for prior uncertainty in both param-
eters. It was anticipated that an average of 8 - 12 residents would be recruited
in each care home. To reflect this prior belief we set the hyper-parameters to
µ0 = 10, ν0 = 6, α0 = 20, β0 = 39, giving a prior cluster size of 10 with mean
variance 2.05.
For the probability of successful follow-up, pf , we take a Beta distribution
with hyper-parameters α0 = 22.4, β0 = 9.6 as the prior. This gives a prior with
a mean of 0.7 and a standard deviation of 0.08.
To partition the parameter space into hypotheses, we first consider the case
where follow-up is perfect, i.e. pf = 1. Conditional on this, we reason that a
mean cluster size of below 5 should lead to a red decision (stop development),
whereas a size of above 7 should lead to a green decision (proceed to the main
trial). As the probability of successful follow-up decreases, we suppose that this
can be compensated by an increase in mean cluster size. We assume the nature
of this trade-off is linear and decide that if pf were reduced to 0.8, we would
want to have a mean cluster size of at least 8 to consider decisions a or g. We
further decide that a follow-up rate of less than pf = 0.6 would be critically
low, regardless of the mean cluster size, and should always lead to decision r.
Similarly, a follow-up rate of 0.6 ≤ pf < 0.66 should lead to modification of
the intervention or trial design. Together, these conditions lead to the following
partitioning of the parameter space:
(pf , µc) ∈


ΦiR if pf < 0.6 or 20− 15pf > µc
ΦiG if pf > 0.66 and 22− 15pf < µc
ΦiA otherwise.
(14)
The hypotheses are illustrated in Figure 3 (a). Having specified both the
hypotheses and the prior distribution for these two parameters, we can obtain
prior probabilities of each hypothesis by sampling from the prior and calculat-
ing the proportion of these samples falling into the regions ΦiR,Φ
i
A and Φ
i
G.
We have plotted 1000 samples from the prior in Figure 3 (a), falling into hy-
potheses ΦiR,Φ
i
A and Φ
i
G in proportions 0.354, 0.517, 0.129 respectively. This
demonstrates that there is significant prior uncertainty regarding the optimal
decision, indicating the potential value of the pilot trial.
4.1.2 Adherence and potential efficacy
Having defined priors and hypotheses with respect to cluster size and follow-
up, we now consider adherence and potential efficacy. Recall that the number
of care homes which successfully adhere to the intervention delivery plan is
assumed to be binomially distributed with probability pa. We assume that
adherence is absolute in the sense that all residents in a care home which does
not successfully deliver the intervention will not receive any of the treatment
effect. We place a Beta prior on pa, with hyper-parameters α = 28.8 and β = 3.2
giving a prior mean of 0.9 and a standard deviation of 0.05.
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Figure 3: Marginal hypotheses over parameters for (a) follow-up rate pf and
mean cluster size µc; and (b) adherence rate pa and potential efficacy µ. Each
point is a sample from the joint prior distribution.
For the continuous measure of physical activity, we place priors on the mean
effect µ, the intracluster correlation coefficient ρ, and the within-cluster variance
σ2W in the manner suggested in [22]. Specifically, we choose
µ ∼ N(0.2, 0.252) (15)
σ2W ∼ Γ
−1(50, 45) (16)
ρ ∼ Beta(1.6, 30.4). (17)
To reflect prior expectation of an ICC around 0.05 but possibly as large as
0.1, the hyperparameters give a prior mean of 0.05 for the ICC with a prior
probability of 0.104 that it will exceed 0.1.
While there is potential for adherence to be improved after the pilot, we
assume there will be little opportunity to improve the potential efficacy of the
intervention. Moreover, we suppose an absolute improvement in adherence of
up to around 0.1 is feasible. To define the hypotheses in this subspace we first
set a minimal level of potential efficacy to be 0.1, and decide that we would
be happy to make decision g at this point if and only if adherence is perfect.
As pa reduces from 1, a corresponding linear increase in potential efficacy is
considered to maintain the overall effectiveness of the intervention. The rate
of substitution for this trade-off is determined to be approximately 0.57 units
of potential efficacy per unit of adherence probability. We consider an absolute
lower limit in adherence of pa = 0.5, below which we will always consider decision
r to be optimal. Taking these considerations together, the marginal hypotheses
are defined as
(pa, µ) ∈


ΦeR if pa < 0.5 or 0.96− 0.57µ > pa
ΦeG if pa > 0.6 and 1.06− 0.57µ < pa
ΦeA otherwise.
(18)
The hypotheses are illustrated in Figure 3 (b). Again, a sample of size
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1000 from the joint marginal prior distribution p(pa, µ) is also plotted, falling
into hypotheses ΦeR,Φ
e
A and Φ
e
G in proportions 0.234, 0.470, 0.296 respectively.
As before, this indicates substantial prior uncertainty regarding the optimal
decision and thus supports the use of a pilot study.
The marginal hypotheses are combined together using equation (12). Con-
sidering the same 1000 samples from the design prior plotted in Figure 3, these
now fall into the regions ΦR,ΦA and ΦG in proportions 0.507, 0.458, and 0.035
respectively. Note that the prior probabilities of these overall hypotheses are
quite different to those of the marginal hypotheses. In particular, there is a
considerable increase in the probability that decision r will be optimal, and a
considerable decrease that decision g will be.
4.2 Evaluation
4.2.1 Weakly informative analysis
We applied the proposed method assuming that a weakly informative joint prior
distribution will be used at the analysis stage2. We took the sample size of the
trial to be k = 6 clusters per arm. For calculating operating characteristics we
generated N = 104 samples from the joint distribution p(θ, x) = p(x|θ)pD(θ).
We analysed each simulated data set using Stan via the R package rstan [28], in
each case generating 5000 samples in four chains and discarding the first 2500
samples in each to allow for burn-in, leading to M = 104 posterior samples in
total. This gave a maximum Monte Carlo error of approximately 0.005 when
estimating a posterior probability Pr[φ ∈ ΦI | x], which we considered sufficient.
These posterior samples were then used to find the posterior probabilities of each
hypothesis, for each simulated data set.
We evaluated the operating characteristics for a sample of parameters (c1, c2, c3)
as described in Section 2.4. A total of 254 parameter vectors were evaluated,
of which 62 led to operating characteristics which were worse in every respect
than some other vector (i.e. dominated) and were discarded. The operating
characteristics of the non-dominated parameters are shown in Figure 4. The
three operating characteristics are found to be highly correlated. In particular,
changing the parameters to give a lower probability of discarding a promising
intervention (OC2) tends to lead to a reduction in the probability of making
an unnecessary adjustment (OC3). When selecting (c1, c2), the key decision
appears to be trading off the probability of an infeasible trial, (OC1), against
OC2. There is a very limited opportunity to minimise OC3 at the expense of
these. For example, compare points b and c in Figure 4, details of which are
given in Table 3. We see that point c reduces OC3 by 0.078 in comparison to
point b, but only at the expense of increase in OC1 and OC2 of 0.13 and 0.145
respectively.
We would expect to see a clear relationship between the value of parameters
c1, c2, c3 and the operating characteristics they relate to. We explore this in
2Full details of the weakly informative prior are given in the appendix.
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Figure 4: Operating characteristics of the example pilot trial for a range of loss
parameter vectors, when a weakly informative analysis prior is used.
Table 3: Estimated operating characteristics (with standard errors) of the
REACH trial for the three loss parameter vectors highlighted in Figure 4, when a
weakly informative analysis prior is used. Costs have been rounded to 2 decimal
places; operating characteristics and their errors to 3.
Label (c1, c2, c3) OC1 OC2 OC3
a (0.07, 0.9, 0.03) 0.107 (0.003) 0.108 (0.003) 0.232 (0.004)
b (0.18, 0.58, 0.24) 0.021 (0.001) 0.394 (0.005) 0.08 (0.003)
c (0.01, 0.29, 0.7) 0.151 (0.004) 0.539 (0.005) 0.002 (0)
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Figure 5: Relationships between the three loss parameters (x axes) and resulting
operating characteristics (y axes).
Figure 5 with scatter plots of each parameter against each operating character-
istic. The results show that there is indeed a strong relationship between the
loss assigned to discarding a promising intervention, c2, and the probability that
this event will occur, OC2 (see centre plot). Moreover, c2 also seems to be the
main determinant of operating characteristics OC1 and OC3. The implication
is that once the c2 ∈ [0, 1] has been chosen, the operating characteristics of the
trial depend only weakly on the way in which the remaining 1− c3 is allocated
to c1 and c3. This appears to be due to the fact that, regardless of how errors
are weighted, the way we have defined our prior distributions and hypotheses
means we are much more likely to make the error of discarding a promising
intervention than the other types of error. The cost we assign to this error is
therefore more influential on the overall operating characteristics than the other
costs.
To illustrate the effect of varying sample size in the REACH trial, we set the
loss function parameters to that of point a in Figure 4 and Table 3, (c1, c2, c3) =
(0.07, 0.9, 0.03). We then estimated the operating characteristics obtained for
k = 6, 12, 18 clusters per arm. Note that we considered only three choices of
sample size due to the significant computational burden of each evaluation. The
results are plotted in Figure 6. Increasing the sample size appears to have little
effect on OC1 and OC3, while leading to a decrease in OC2, the probability
of discarding a promising intervention. This behaviour reflects the priorities
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Figure 6: Operating characteristics of the REACH trial for per-arm sample sizes
k = 6, 12, 18 and setting (c1, c2, c3) = (0.069, 0.116, 0.815). Error bars denote
95% confidence intervals. All points have been adjusted horizontally to avoid
overlap.
encoded by the costs parameter, where c2 = 0.9.
4.2.2 Incorporating subjective priors
Rather than use weakly or non-informative priors when analysing the pilot data,
we may instead want to make use of the (subjective) elicited knowledge of pa-
rameter values described in the design prior pD(θ). Anticipating criticisms of a
fully subjective analysis, we can envisage two particular cases where this might
be appropriate. Firstly, using the components of the design prior which describe
the nuisance parameters ψ while maintaining weakly informative priors on sub-
stantive parameters φ. Secondly, when very little data on a specific substantive
parameter is going to be collected in the pilot, using the informative design prior
for that parameter could substantially improve operating characteristics.
We replicated the above analysis for these two scenarios. For the second,
we used informative priors for all nuisance parameters and for the probability
of adherence, pa. Recall that this is informed by a binary indicator at the care
home level and only in the intervention arm, and will therefore have very little
pilot data bearing on it. For each case we used the sameN samples of parameters
and pilot data which were used in the weakly informative case, repeating the
Bayesian analysis using the appropriate analysis prior and obtaining estimated
posterior probabilities pR, pA and pG as before. These were used in conjunction
with the same set of loss parameter vectors C to obtain corresponding operating
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Figure 7: Operating characteristics and expected utilities for weakly (WI) and
partially informative (INA)
characteristics.
For brevity we will refer to the three cases as Weakly Informative (WI),
Informative Nuisance (IN), and Informative Nuisance and Adherence (INA).
Comparing the operating characteristics of cases WI and IN, we found very little
difference (further details are provided in the appendix). When we contrast cases
WI and INA, however, there is a clear distinction. Using the INA analysis prior
will lead to larger probabilities of an infeasible trial (OC1) and of unnecessary
adjustment (OC2), while reducing the probability of discarding a promising
intervention (OC3), for almost all loss parameters. The expected loss is always
lower for the INA analysis than for WI, as we would expect.
5 Discussion
When deciding if and how a definitive RCT of a complex intervention should
be conducted, and basing this decision on an analysis of data from a small pilot
trial, there is a risk we will inadvertently make the wrong choice. A Bayesian
analysis of pilot data followed by decision making based on a loss function
can help ensure this risk is minimised. The expected results of such a pilot
can be evaluated through simulation at the design stage, producing operating
characteristics which help us understand the potential for the pilot to lead to
better decision making. These evaluations can in turn be used to find the loss
function which leads to the most desirable operating characteristics, and to
inform the choice of sample size.
Our proposal has been motivated by some salient characteristics of complex
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intervention pilot trials, and offers several potential benefits over standard pilot
trial design and analysis techniques. The Bayesian approach to analysis means
that complex multi-level models can be used to describe the data, even when
the sample size is small. In contrast to the usual application of independent
progression criteria for several parameters of interest, we provide a way for
preferential relationships between parameters to be articulated and used when
making decisions. Using a subjective prior distribution on unknown parameters
at the design stage allows both our knowledge and our uncertainty to be fully
expressed, meaning we can leverage external information whilst also avoiding
decisions which are highly sensitive to imprecise point estimates.
Our proposed design is related to the literature on assurance calculations
for clinical trials [17], applying the idea of using unconditional event probabil-
ities as operating characteristics to the pilot trial setting. In doing so we have
shown how assurances can be defined for multiple substantive parameters with
trade-offs between them, and with respect to the ‘traffic light’ red/amber/green
decision structure commonly found in pilot trials. The multi-objective optimi-
sation framework we have used to inform trial design allows the decision-maker
to explicitly consider the different trade-offs between operating characteristics
which are available, and select that which best reflects their own preferences. A
similar approach has been taken in the context of phase II trials using the sta-
tistical concept of admissible designs [29, 30]. This can be contrasted with the
conventional and much criticised approach common in the frequentist context,
where arbitrary constraints are placed on type I and II error rates in order to
define a single optimal design [31].
The benefits brought by the Bayesian approach must be set against the chal-
lenges it brings, particularly in terms of computation time and implementation.
In terms of the latter, we are required to specify a joint prior distribution over
the parameters θ and a partitioning of the parameter space into the three hy-
potheses. The specification of the prior distribution may be a challenging and
time-consuming task. Although some relevant data relating to similar contexts
may be available, for example in systematic reviews or observational studies,
expert opinion may still be required to articulate the relevance of such data to
the problem at hand. When no data are available, which is not unlikely given
the early phase nature of pilot studies, expert opinion will be the only source
of information. Although potentially challenging, many examples describing
successful practical applications of elicitation for clinical trial design are avail-
able [20, 18, 23], as are tools for its conduct such as the Sheffield Elicitation
Framework (SHELF) [24]. Dividing the parameter space into three hypothe-
ses may also prove challenging in practice, particularly when trade-offs between
more than two parameters are to be elicited. There is a need for methodological
research investigating how methods for multi-attribute preference elicitation,
such as those set out in [26], can be applied in this context.
The computational burden of the proposed method is significant, partic-
ularly when the model is too complex to allow a conjugate analysis to be
used when sampling from the posterior distribution. We have used a nested
Monte Carlo sampling scheme to estimate operating characteristics, as seen
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elsewhere [19, 17, 32]. One potential approach to improve efficiency is to use
non-parametric regression to predict the expected losses of Equation (3) based
on some simulated data, thus bypassing the need to undertake a full MCMC
analysis for each of the N samples in the outer loop. This approach has been
shown to be successful in the context of expected value of information calcu-
lations [33, 34]. The computational difficulties will be particularly pertinent
when using our approach to determine sample size, as several evaluations of
different sample size choices will be required. If the choice of sample size can be
framed as an optimisation problem, methods for efficient global optimisation of
computationally expensive functions such as those described in [35, 36] may be
useful [16]. Alternatively, one of several rules-of-thumb for choosing pilot sam-
ple size [3, 9, 11, 13] could be used, with the resulting operating characteristics
evaluated using the proposed method.
We have defined our procedure in terms of a loss function, where the decision
making following the pilot will minimise the expected loss. However, the piece-
wise constant loss function we have proposed may not adequately represent the
preferences of the decision maker. For example, we may object to the loss as-
sociated with discarding a promising intervention being independent of exactly
how effective the intervention is. An alternative is to try to define a richer rep-
resentation of the loss function through direct elicitation of the decision makers
preferences under uncertainty [25], leading to a fully decision-theoretic approach
to design and analysis [37]. However, as previously noted by others [38, 39, 40],
implementation of these approaches has been limited in practice and this may
be indicative of their feasibility.
The proposed method could be extended in several ways. More operating
characteristics could be defined and used in design optimisation, more compli-
cated trade-off relationships between multiple parameters could be addressed, or
the hypotheses could be expanded to include nuisance parameters which would
be used as part of the sample size calculation in the main RCT. A particularly
interesting avenue for future research is to consider how to model post-pilot
trial actions in more detail. For example, while we allow for the possibility of
making an ‘amber’ decision, indicating that modifications to the intervention or
trial design should be made, we do not model what that decision will actually
look like and how it should relate to the observed pilot data. Methodology for
jointly modelling a pilot and subsequent main RCT in this manner could be in-
formed by developments for designing phase II/III programs in the drug setting
[41, 42, 43, 44].
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